Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioVaxys TechnologyFRA:5LB0 Debt-to-EBITDA is -0.04 as of Jul. 2025. Among 309 Biotechnology companies, BioVaxys Technology ranks worse than 323624.27% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for BioVaxys Technology's Debt-to-EBITDA or its related term are showing as below:
FRA:5LB0's Debt-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 1.39 * Ranked among companies with meaningful Debt-to-EBITDA only.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
BioVaxys Technology Debt-to-EBITDA Related Terms
BioVaxys Technology Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for BioVaxys Technology's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:5LB0 vs BPTH, AZTR, CLDI: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, BioVaxys Technology's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioVaxys Technology Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioVaxys Technology's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where BioVaxys Technology's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jul. 2025) EBITDA data.
BioVaxys Technology (FRA:5LB0) has a Debt-to-EBITDA of -0.04 as of Jul. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on BioVaxys Technology. According to the industry distribution chart, BioVaxys Technology ranks #999999 out of 309 companies in the Biotechnology industry.
Is BioVaxys Technology's Debt-to-EBITDA too high?
BioVaxys Technology's current Debt-to-EBITDA is -0.04. Based on the distribution chart, BioVaxys Technology ranks #999999 out of 309 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does BioVaxys Technology's Debt-to-EBITDA compare to BPTH and AZTR?
According to the Biotechnology industry distribution chart, BioVaxys Technology ranks #999999 out of 309 companies for Debt-to-EBITDA. This places BioVaxys Technology in the lower half of its industry. The industry median Debt-to-EBITDA is 1.39. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.39, based on 309 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on BioVaxys Technology. For the Biotechnology industry, the median Debt-to-EBITDA is 1.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioVaxys Technology's current Debt-to-EBITDA is -0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioVaxys Technology stock overvalued right now?
BioVaxys Technology (FRA:5LB0) has a current Debt-to-EBITDA of -0.04. The current Debt-to-EBITDA is -0.04. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For BioVaxys Technology (FRA:5LB0), the current Debt-to-EBITDA is -0.04 as of Jul. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BioVaxys Technology Corp is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix 'neoantigen' tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The company's clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix 'neoantigen' tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5LB0 has been successfully added to your 
